NINGBO MENOVO PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.5 CNY | +3.05% |
|
-8.22% | -39.85% |
| May. 24 | China Approves Menovo Pharma's Type 2 Diabetes Drug | MT |
| Apr. 29 | Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 1.75B 241M | Sales 2025 * | 2.1B 290M | Capitalization | 2.45B 339M |
|---|---|---|---|---|---|
| Net income 2024 * | 229M 31.6M | Net income 2025 * | 303M 41.81M | EV / Sales 2024 * | 1.41 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.17 x |
| P/E ratio 2024 * |
10.7
x | P/E ratio 2025 * |
8.1
x | Employees | 2,353 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.26% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.05% | ||
| 1 week | -8.22% | ||
| Current month | -8.22% | ||
| 1 month | -21.88% | ||
| 3 months | -11.54% | ||
| 6 months | -40.26% | ||
| Current year | -39.85% |
1 week
11.04
12.60
1 month
11.0414.93
Current year
9.9619.51
1 year
9.9622.02
3 years
9.9662.05
5 years
9.9662.05
10 years
9.6662.05
| Managers | Title | Age | Since |
|---|---|---|---|
Cheng Zhi Yao
CEO | Chief Executive Officer | 49 | 04-02-18 |
Gao Feng Ying
DFI | Director of Finance/CFO | 53 | 19-10-11 |
Xiao Qing Zhang
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xin Min Bao
BRD | Director/Board Member | 54 | 18-06-19 |
Cheng Zhi Yao
CEO | Chief Executive Officer | 49 | 04-02-18 |
Zhi Yan Fan
PRN | Corporate Officer/Principal | 41 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 11.5 | +3.05% | 2,987,779 |
| 24-06-06 | 11.16 | -5.02% | 4,883,259 |
| 24-06-05 | 11.75 | -1.92% | 2,831,696 |
| 24-06-04 | 11.98 | -1.56% | 2,878,183 |
| 24-06-03 | 12.17 | -2.87% | 3,241,174 |
End-of-day quote Shanghai S.E., June 06, 2024
More quotes
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations. The Company is mainly engaged in three businesses. The contract development and manufacturing organization (CDMO) business mainly provides pharmaceutical companies with CDMO services for the entire preparation industry chain. The specialty API business is mainly engaged in the production and sales of APIs. The preparation business is mainly engaged in the production and sales of preparations. The Company's main products include valsartan, losartan, perindopril, rosuvastatin calcium, atorvastatin calcium and pregabalin. The Company's products are mainly used in cardiovascular, central nervous, antiviral, hypoglycemic, gastrointestinal and other therapeutic areas. The Company mainly conducts its businesses in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
11.5
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -39.85% | 339M | |
| +45.82% | 765B | |
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| +11.88% | 216B | |
| -0.78% | 219B | |
| +5.90% | 164B |
- Stock Market
- Equities
- 603538 Stock
